Priya Ranjan Shrivastava
( Chairman & Managing Director)
Chairman & Managing Director's Message :
In the (2007-08) financial year, your company Oriscon Biotech India Pvt Ltd has achieved its financial
and operational targets, and continue to grow as a promising Pharmaceutical Company. From the
integrated business platform build on solid foundation, your Company has strengthened the base
and hopes to do better business, while delivering new products, new services and new markets.
This is company's strategy in action and it hopes to achieve the target of Rs. 1 crore as a capital
base in the current financial year (2008-09).
The Annual Report posed and answered in part the question "what am I doing about the
conditions faced during year and whether the Company will be able
to launch its product in Bihar as promised by me during last AGM ?"
Oriscon Biotech India Pvt Ltd delivered a solid financial achievement again this year, the capital
grows from Rs. 40 Lakhs to Rs. 80 Lakhs in just two years. As a result of this the net value of
Company's share of Rs. 10 increases to Rs. 15 in the year 2007 and this year to Rs. 20 as on
31st March 2008 . The result has confirmation that the company's strategy of generating
revenue streams is working, with strong contributions from Promoters / Members and
Financers, despite a less favourable season in (2007-08).
Investment return for the year has been satisfactory as it is evident from the fact that your
Company has already paid a return of 12% to all the Promoters / Members as per the respective
agreements according to their share holdings. Investment income also increased in line with
higher interest rates and improved cash flow. As a result of this - Authorised Fund of
Shareholders ( Promoters/Members ) becomes double in just two financial years and Present
net asset value per share is Rs.20 and therefore ,the value of Rs.10 per share is Rs.20 - An
increased in growth of 100% in just two years.
(2007-08 ) was a challenging year. While the industry was expected to
benefit from general economic growth but underwriting discipline and
appropriate pricing models was a setback to sustained Pharma growth
that remain competitive in a difficult generic & branded market.
Looking Forward - The Year Ahead
( 2008-09 ) As you will see the business continuing its drive for profitable growth, as your
Company build on its core strengths to achieve the strategic objectives. Market activities
will focus on leveraging product offerings and the technological platforms that it has developed.
People Management continues to focus on an integration of its key activities and closer
alignment with HR initiatives - profiling with the best practices.
Operational excellence and underwriting discipline continue to be
fundamental strengths of your Company, which need to be leveraged to
achieve its growth targets in a challenging market.
Acknowledgements
I express my appreciation to all Promoters/Members and the business partners for the
continued support and the guidance in the hour of need. The achievements are only possible
through the combined efforts of the people associated with the Company Oriscon Biotech
India Pvt Ltd - A dynamic business organisation. Every year, I demand a lot from the
Pomoters/Members and every year they rise to the challenge. I do believe that success
on these fronts will build value for the company, and for all of you share & stakeholders.
I would also like to extend my sincere thanks to all of you for providing
unstinting and dedicated service to the Company and looking forward to
your continuous esteemed support along with a prosperous rewarding
association in the years to come !
On behalf of the board and
management, I thank all of you for your
commitment and co-operation !!
Priya Ranjan Shrivastava
( Chairman & Managing Director)
22June, 2008